Skip to main content

Galecto, Inc. (GLTO)

NASDAQ Stock Market Healthcare BiotechnologyView data quality →
43.1Fair

ValueMarkers Composite Index

Top 9%#40,479 of 44,707
Undervalued

77% below intrinsic value ($110)

UndervaluedFair ValueOvervalued
Piotroski
2/9
Weak
Beneish
-
Altman
-0.75
Distress
DCF Value
$110
Undervalued
ROIC
-15.2%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Galecto, Inc. (GLTO) — VMCI valuation read

GLTO prints VMCI 43/100 inside the Healthcare sector, where the median sits at 50. The 7-point below-median delta is the cleanest single-number summary of Galecto, Inc.'s composite stance, and in the mid-cap bucket it places the share behind the typical peer on the five-pillar mix.

On GLTO, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** GLTO trades at 20.0x earnings, 11% above the Healthcare median of 18.0x; that is the value line. ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 1.8x is the rate-sensitivity line to watch; that is the risk line for Galecto, Inc. on the trailing financials.

GLTO rose 3.4% over the trailing 7 days, with a -20.7% read on a 30-day basis.

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.

CEO: Lori C. Firmani5 employeesUSgalecto.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in GLTO’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.